

Childhood-Onset Schizophrenia

Archives of General Psychiatry

53, 1090

DOI: [10.1001/archpsyc.1996.01830120020005](https://doi.org/10.1001/archpsyc.1996.01830120020005)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Childhood-Onset Schizophrenia. Archives of General Psychiatry, 1997, 54, 897.	12.3	245
2	Quantitative Morphology of the Cerebellum and Fourth Ventricle in Childhood-Onset Schizophrenia. American Journal of Psychiatry, 1997, 154, 1663-1669.	7.2	132
3	Autonomic Nervous System Markers of Psychopathology in Childhood-Onset Schizophrenia. Archives of General Psychiatry, 1997, 54, 904.	12.3	64
4	Cerebral glucose metabolism in childhood onset schizophrenia. Psychiatry Research - Neuroimaging, 1997, 75, 131-144.	1.8	46
5	Pubertal development and onset of psychosis in childhood onset schizophrenia. Psychiatry Research, 1997, 70, 1-7.	3.3	42
6	Large CAG/CTG repeats are associated with childhood-onset schizophrenia. Molecular Psychiatry, 1998, 3, 321-327.	7.9	30
7	Perceived Self-Care Capabilities of Abused/Neglected and Nonabused/Non-neglected Pregnant, Low-Socioeconomic Adolescents. Journal of Child and Adolescent Psychiatric Nursing, 1998, 11, 30-37.	1.4	6
8	Research Update: Childhood-Onset Schizophrenia: Implications of Clinical and Neurobiological Research. Journal of Child Psychology and Psychiatry and Allied Disciplines, 1998, 39, 101-113.	5.2	117
9	HLA antigens in childhood onset schizophrenia. Psychiatry Research, 1998, 78, 123-132.	3.3	14
10	THE ANTIPSYCHOTICS. Pediatric Clinics of North America, 1998, 45, 1205-1232.	1.8	27
11	Childhood-Onset Schizophrenia: An Open-Label Study of Olanzapine in Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 1998, 37, 377-385.	0.5	134
12	CHILD AND ADOLESCENT SCHIZOPHRENIA. Psychiatric Clinics of North America, 1998, 21, 43-56.	1.3	20
13	Case Series: Spectrum of Neuroleptic-Induced Movement Disorders and Extrapyrarnidal Side Effects in Childhood-Onset Schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 1998, 37, 221-227.	0.5	56
14	Antipsychotic drugs. Side Effects of Drugs Annual, 1998, , 42-65.	0.6	0
15	Child and Adolescent Psychopharmacology. , 1998, , 603-636.		0
16	Nonresponse of Adrenocorticotropic Hormone in First-Ever Lactate-Induced Panic Attacks in Healthy Volunteers. Archives of General Psychiatry, 1998, 55, 85.	12.3	11
17	Risky Business: Making Sense of Estimates of Risk. Canadian Journal of Psychiatry, 1998, 43, 411-415.	1.9	14
18	Progressive Reduction of Temporal Lobe Structures in Childhood-Onset Schizophrenia. American Journal of Psychiatry, 1998, 155, 678-685.	7.2	177

#	ARTICLE	IF	CITATIONS
19	Typical and Atypical Antipsychotics in Adolescent Schizophrenia: Efficacy, Tolerability, and Differential Sensitivity to Extrapyramidal Symptoms. <i>Canadian Journal of Psychiatry</i> , 1998, 43, 596-604.	1.9	67
20	Use of antipsychotics by child and adolescent psychiatrists. <i>Psychiatric Bulletin</i> , 1998, 22, 685-687.	0.3	13
21	Schizophrenia in Children and Adolescents. , 1998, , 703-723.		0
22	Childhood-Onset Schizophrenia. <i>Archives of General Psychiatry</i> , 1998, 55, 90.	12.3	4
23	Childhood-Onset Schizophreniaâ€”Reply. <i>Archives of General Psychiatry</i> , 1998, 55, 91.	12.3	1
24	Schizophrenia: Improving Outcome. <i>Harvard Review of Psychiatry</i> , 1999, 6, 229-240.	2.1	38
25	Prescribing antipsychotics in child psychiatry. <i>Psychiatric Bulletin</i> , 1999, 23, 182-182.	0.3	0
27	Elevated Prolactin in Pediatric Patients on Typical and Atypical Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 1999, 9, 239-245.	1.3	124
28	Psychotropic Medication Treatment Patterns Among School-Aged Children in Foster Care. <i>Journal of Child and Adolescent Psychopharmacology</i> , 1999, 9, 135-147.	1.3	49
29	Effective treatment for mental disorders in children and adolescents. <i>Clinical Child and Family Psychology Review</i> , 1999, 2, 199-254.	4.5	313
30	Efficacy and effectiveness of child and adolescent psychotherapy and pharmacotherapy. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1999, 1, 125-157.	2.3	160
31	Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999, 3, 159-169.	2.4	9
32	Antipsychotics in Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1999, 38, 537-545.	0.5	113
33	Clozapine versus typical neuroleptic medication for schizophrenia. , 1999, , CD000059.		54
34	Psychotropic medication use among children in foster care: relationship to severe psychiatric disorders.. <i>American Journal of Public Health</i> , 1999, 89, 1732-1735.	2.7	36
35	Psychopharmacology: Novel Antipsychotic Medications in the Treatment of Children and Adolescents. <i>Psychiatric Services</i> , 1999, 50, 171-174.	2.0	34
36	Progressive Cortical Change During Adolescence in Childhood-Onset Schizophrenia. <i>Archives of General Psychiatry</i> , 1999, 56, 649.	12.3	361
37	Adolescent schizophrenia. <i>Advances in Psychiatric Treatment</i> , 2000, 6, 83-92.	0.5	48

#	ARTICLE	IF	CITATIONS
38	Atypical antipsychotics: are some more atypical than others?. <i>Psychopharmacology</i> , 2000, 148, 3-15.	3.1	150
39	Atypical neuroleptics in child and adolescent psychiatry. <i>European Child and Adolescent Psychiatry</i> , 2000, 9, S9-S19.	4.7	59
40	The Diagnosis and Treatment of Children and Adolescents with Schizophrenia. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2000, 9, 183-199.	1.9	14
41	Refractory schizophrenia and atypical antipsychotics. <i>Journal of Psychopharmacology</i> , 2000, 14, 409-418.	4.0	73
42	Long-Term Risperidone for Pervasive Developmental Disorder: Efficacy, Tolerability, and Discontinuation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2000, 10, 79-90.	1.3	93
43	Paediatric uses of atypical antipsychotics. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 935-945.	1.8	34
44	Clozapine in Childhood-Onset Schizophrenia: A Report of Five Cases. <i>Clinical Child Psychology and Psychiatry</i> , 2000, 5, 403-410.	1.6	10
45	Treatment of Childhood-Onset Schizophrenia with Olanzapine. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2000, 10, 69-78.	1.3	46
46	Management of Schizophrenia in Children and Adolescents. <i>Paediatric Drugs</i> , 2000, 2, 253-262.	3.1	22
47	Differentiating Childhood-Onset Schizophrenia From Psychotic Mood Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2001, 40, 1190-1196.	0.5	45
48	Tolerability Profile of Atypical Antipsychotics in Children and Adolescents. <i>Paediatric Drugs</i> , 2001, 3, 927-942.	3.1	47
49	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2001, 40, 4S-23S.	0.5	132
50	Open Trial of Risperidone in 24 Young Children With Pervasive Developmental Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2001, 40, 1206-1214.	0.5	101
51	The Pharmacotherapy of Child and Adolescent Psychotic Disorders. <i>Child and Adolescent Psychopharmacology News</i> , 2001, 6, 1-4.	0.1	0
52	The Pharmacologic Treatment of the Early Phase of First-Episode Psychosis in Youths. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 803-809.	1.9	7
53	Proposed treatment for adolescent psychosis. 1: Schizophrenia and schizophrenia-like psychoses. <i>Advances in Psychiatric Treatment</i> , 2001, 7, 16-23.	0.5	15
54	Clozapine Impact on Clinical Outcomes and Aggression in Severely Ill Adolescents with Childhood-Onset Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 965-968.	1.9	32
55	Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials. <i>American Journal of Psychiatry</i> , 2001, 158, 518-526.	7.2	574

#	ARTICLE	IF	CITATIONS
56	Update and Recommendations for the Use of Antipsychotics in Early-Onset Psychoses. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2001, 11, 113-130.	1.3	31
57	Risperidone Monotherapy in Preschool Children With Pervasive Developmental Disorders. <i>Journal of Child Neurology</i> , 2001, 16, 395-400.	1.4	35
58	Clozapine in Adolescent Inpatients with Acute Mania. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2002, 12, 93-99.	1.3	84
59	Correlation of Antipsychotic and Prolactin Concentrations in Children and Adolescents Acutely Treated with Haloperidol, Clozapine, or Olanzapine. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2002, 12, 83-91.	1.3	70
60	Pediatric psychopharmacology: A review of new developments and recent research.. <i>Professional Psychology: Research and Practice</i> , 2002, 33, 135-147.	1.0	31
61	Psychopathology in Children. , 2002, , 881-920.		7
62	The first-episode of schizophrenia: a challenge for treatment. <i>European Psychiatry</i> , 2002, 17, 371s-375s.	0.2	5
63	Insomnia in Children. <i>Paediatric Drugs</i> , 2002, 4, 391-403.	3.1	25
64	Childhood-Onset Schizophrenia. <i>Child and Adolescent Psychopharmacology News</i> , 2002, 7, 1-4.	0.1	0
65	Clinical aspects of child and adolescent psychopharmacology. , 2002, , 70-90.		4
66	Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry. <i>Journal of Neural Transmission</i> , 2002, 109, 101-117.	2.8	91
67	Do we need placebos to evaluate new drugs in children with schizophrenia?. <i>Psychopharmacology</i> , 2002, 159, 117-124.	3.1	8
68	"Typical" but not "atypical" antipsychotic effects on startle gating deficits in prepubertal rats. <i>Psychopharmacology</i> , 2002, 161, 38-46.	3.1	19
69	Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. <i>Journal of Neural Transmission</i> , 2003, 110, 545-560.	2.8	60
70	Clozapine-Induced Neutropenia in Children: Management with Lithium Carbonate. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2003, 13, 401-404.	1.3	51
71	Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 145-161.	0.5	240
72	Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part I: A Review. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 132-144.	0.5	150
73	Evidence-Based Treatments in Child and Adolescent Psychiatry: An Inventory. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 1388-1400.	0.5	114

#	ARTICLE	IF	CITATIONS
74	A Prospective, Open-Label Trial of Olanzapine in Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 170-175.	0.5	59
75	Psychopharmacology and Aggression. <i>Journal of Emotional and Behavioral Disorders</i> , 2003, 11, 157-168.	1.7	43
76	A Double-Edged Sword: Atypical Antipsychotics in Child and Adolescent Psychiatry. <i>Child and Adolescent Psychopharmacology News</i> , 2003, 8, 4-5.	0.1	1
77	A Meta-analysis of the Efficacy of Second-Generation Antipsychotics. <i>Archives of General Psychiatry</i> , 2003, 60, 553.	12.3	932
78	New generation antipsychotics for first episode schizophrenia. <i>The Cochrane Library</i> , 2003, , CD004410.	2.8	24
79	Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: A re-examination. <i>British Journal of Psychiatry</i> , 2003, 183, 161-166.	2.8	67
81	Clozapine Pharmacokinetics in Children and Adolescents with Childhood-Onset Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 87-91.	1.4	66
82	Structural Brain MRI Abnormalities in Healthy Siblings of Patients With Childhood-Onset Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 569-571.	7.2	69
83	Concomitant Psychotropic Medication for Youths. <i>American Journal of Psychiatry</i> , 2003, 160, 438-449.	7.2	143
84	Atypical Antipsychotics in Pediatric Psychiatry: Efficacy and Tolerability in Well-Designed Trials. <i>Child and Adolescent Psychopharmacology News</i> , 2003, 8, 8-11.	0.1	0
85	A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial. <i>Neuropsychopharmacology</i> , 2004, 29, 133-145.	5.4	290
86	Pericarditis and Polyserositis as a Side Effect of Clozapine in an Adolescent Girl. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 311-314.	1.3	17
87	Incidences of New Prescribing by British Child and Adolescent Psychiatrists: a Prospective Study Over 12 Months. <i>Journal of Psychopharmacology</i> , 2004, 18, 115-120.	4.0	24
88	Early onset schizophrenia: diagnostic dilemmas and treatment challenges. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 131-147.	0.2	4
89	Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rGB /Overlock 10 Tf 50 177		
90	Atypical Antipsychotic Use in a State Hospital Inpatient Adolescent Population. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 75-85.	1.3	20
91	Prescription of psychotropic drugs in adolescent psychiatry wards in Finland. <i>Nordic Journal of Psychiatry</i> , 2004, 58, 213-218.	1.3	4
92	Annotation: Childhood-onset schizophrenia: clinical and treatment issues. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2004, 45, 180-194.	5.2	112

#	ARTICLE	IF	CITATIONS
93	An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. <i>Contemporary Clinical Trials</i> , 2004, 25, 598-612.	1.9	85
94	Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. <i>Journal of Neural Transmission</i> , 2004, 111, 791-815.	2.8	35
95	Childhood-onset schizophrenia and tryptophan hydroxylase gene polymorphism. <i>American Journal of Medical Genetics Part A</i> , 2004, 128B, 24-26.	2.4	11
96	Pharmacotherapy of Pervasive Developmental Disorders in Children and Adolescents. <i>CNS Drugs</i> , 2004, 18, 1031-1052.	5.9	32
97	Weight Gain Associated with Atypical Antipsychotic Use in Children and Adolescents. <i>Paediatric Drugs</i> , 2004, 6, 33-44.	3.1	102
98	Second-Generation Antipsychotic Medications in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 372-394.	1.3	132
99	A review of the growing evidence base for pediatric psychopharmacology. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2004, 13, 817-855.	1.9	15
100	Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. <i>Schizophrenia Research</i> , 2004, 69, 325-331.	2.0	17
101	Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents. <i>Drug Safety</i> , 2004, 27, 1135-1156.	3.2	63
102	The Off-Label Use of Clozapine in Adolescents with Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 57-63.	1.3	50
105	Clinical effectiveness of new generation antipsychotics in adolescent patients. <i>European Neuropsychopharmacology</i> , 2004, 14, S471-S479.	0.7	25
106	Management of early-onset psychosis. <i>Current Opinion in Psychiatry</i> , 2004, 17, 249-254.	6.3	8
107	Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY) Part II. <i>Focus (American Psychiatric Publishing)</i> , 2004, 2, 608-624.	0.8	0
108	Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY), Part I: A Review. <i>Focus (American Psychiatric Publishing)</i> , 2004, 2, 596-607.	0.8	2
109	Prescription of psychotropic drugs in adolescent psychiatry wards in Finland. <i>Nordic Journal of Psychiatry</i> , 2004, 58, 213-218.	1.3	6
110	Comparison of Progressive Cortical Gray Matter Loss in Childhood-Onset Schizophrenia With That in Childhood-Onset Atypical Psychoses. <i>Archives of General Psychiatry</i> , 2004, 61, 17.	12.3	134
111	Prevalence of Atypical Antipsychotic Drug Use Among Commercially Insured Youths in the United States. <i>JAMA Pediatrics</i> , 2005, 159, 362.	3.0	47
112	Paediatric psychopharmacology in schizophrenia. <i>Psychiatry (Abingdon, England)</i> , 2005, 4, 49-51.	0.2	0

#	ARTICLE	IF	CITATIONS
113	Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. <i>Psychopharmacology</i> , 2005, 182, 499-507.	3.1	31
114	Dysbindin (DTNBP1, 6p22.3) is Associated with Childhood-Onset Psychosis and Endophenotypes Measured by the Premorbid Adjustment Scale (PAS). <i>Journal of Autism and Developmental Disorders</i> , 2005, 35, 831-838.	2.7	71
115	Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units. <i>Psychiatric Bulletin</i> , 2005, 29, 377-380.	0.3	19
116	Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator. <i>Psychiatric Services</i> , 2005, 56, 85-92.	2.0	49
117	Metabolic side effects of atypical antipsychotics in children: a literature review. <i>Journal of Psychopharmacology</i> , 2005, 19, 533-550.	4.0	65
119	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 132-191.	2.6	242
120	Hormonal Correlates of Clozapine-Induced Weight Gain in Psychotic Children: An Exploratory Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 925-933.	0.5	50
121	Clozapine: Its Impact on Aggressive Behavior Among Children and Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 55-63.	0.5	50
122	Hematological Adverse Events in Clozapine-Treated Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 1024-1031.	0.5	61
123	IQ stabilization in childhood-onset schizophrenia. <i>Schizophrenia Research</i> , 2005, 77, 271-277.	2.0	53
124	Treatment-Refractory Schizophrenia in Children and Adolescents: An Update on Clozapine and Other Pharmacologic Interventions. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2006, 15, 135-159.	1.9	20
125	Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2006, 15, 177-206.	1.9	163
126	Review of antipsychotics in children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1871-1885.	1.8	22
127	Children with Schizophrenia. <i>CNS Drugs</i> , 2006, 20, 841-866.	5.9	68
128	Decision Making About Children With Psychotic Symptoms: Using the Best Evidence in Choosing a Treatment. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 1381-1386.	0.5	9
129	Management of treatment resistant schizophrenia. <i>African Journal of Psychiatry</i> , 2006, 9, 17.	0.1	6
130	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo. <i>Revista De Psiquiatria Clinica</i> , 2006, 33, 7-64.	0.6	9
131	Psychotic Disorders. , 2006, , 431-446.		0

#	ARTICLE	IF	CITATIONS
132	Childhood-Onset Schizophrenia. Archives of General Psychiatry, 2006, 63, 721.	12.3	200
133	Childhood onset schizophrenia: cortical brain abnormalities as young adults. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2006, 47, 1003-1012.	5.2	141
134	Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Reviews Drug Discovery, 2006, 5, 133-146.	46.4	52
135	Antipsychotics in early onset Schizophrenia. European Child and Adolescent Psychiatry, 2006, 15, 141-148.	4.7	67
136	Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder. Current Drug Safety, 2006, 1, 307-318.	0.6	3
137	National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs. Archives of General Psychiatry, 2006, 63, 679.	12.3	540
138	Phenomenology and Neurobiology of Childhood Onset Schizophrenia. Current Psychiatry Reviews, 2006, 2, 463-472.	0.9	0
139	Clinical Drug Monitoring in Child and Adolescent Psychiatry: Side Effects of Atypical Neuroleptics. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 308-316.	1.3	48
140	An Open-Label Randomized Comparison of Olanzapine Versus Risperidone in the Treatment of Childhood-Onset Schizophrenia. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 393-403.	1.3	51
141	Epileptogenic drugs: a systematic review. Expert Review of Neurotherapeutics, 2006, 6, 575-589.	2.8	70
142	Cortical Brain Development in Nonpsychotic Siblings of Patients With Childhood-Onset Schizophrenia. Archives of General Psychiatry, 2007, 64, 772.	12.3	145
143	Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia. Schizophrenia Bulletin, 2007, 34, 60-71.	4.3	149
144	An Open-Label Study of Olanzapine in Children and Adolescents with Schizophrenia. Journal of Psychiatric Practice, 2007, 13, 86-96.	0.7	11
145	Antipsychotic medication for childhood-onset schizophrenia. The Cochrane Library, 2007, , CD004027.	2.8	24
146	Off-label use of antipsychotics: are we mad?. Expert Opinion on Drug Safety, 2007, 6, 533-545.	2.4	33
147	Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1349-1356.	0.5	90
148	Risperidone in adolescent schizophrenic psychoses: A retrospective study. International Journal of Psychiatry in Clinical Practice, 2007, 11, 273-278.	2.4	2
149	Atypical antipsychotic medication poisoning: An evidence-based consensus guideline for out-of-hospital management. Clinical Toxicology, 2007, 45, 918-942.	1.9	28

#	ARTICLE	IF	CITATIONS
150	Is There a Role for Clozapine in the Treatment of Children and Adolescents?. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 423-428.	0.5	21
151	Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 969-978.	0.5	64
152	Dynamic mapping of hippocampal development in childhood onset schizophrenia. Schizophrenia Research, 2007, 90, 62-70.	2.0	59
153	Survey of Atypical Antipsychotic Prescribing by Canadian Child Psychiatrists and Developmental Pediatricians for Patients Aged under 18 Years. Canadian Journal of Psychiatry, 2007, 52, 363-368.	1.9	50
155	Tardive dyskinesia in children treated with atypical antipsychotic medications. Movement Disorders, 2007, 22, 1777-1782.	3.9	45
156	Managing Psychotic Illness in Young People: A Practical Overview. Child and Adolescent Mental Health, 2007, 12, 173-186.	3.5	6
157	Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. Journal of Neural Transmission, 2007, 114, 273-280.	2.8	56
158	Management of psychiatric disorders in children and adolescents with atypical antipsychotics. European Child and Adolescent Psychiatry, 2007, 16, 104-120.	4.7	98
159	Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. Journal of Neural Transmission, 2008, 115, 1599-1608.	2.8	54
160	Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: A retrospective study in Korean children and adolescents. Human Psychopharmacology, 2008, 23, 715-722.	1.5	26
161	Paediatric psychopharmacology in schizophrenia. Psychiatry (Abingdon, England), 2008, 7, 458-462.	0.2	0
162	Child and adolescent schizophrenia: pharmacological approaches. Expert Opinion on Pharmacotherapy, 2008, 9, 2053-2068.	1.8	30
163	Clozapine and High-Dose Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison. Biological Psychiatry, 2008, 63, 524-529.	1.3	194
164	Clozapine use in children and adolescents. Expert Opinion on Pharmacotherapy, 2008, 9, 459-465.	1.8	49
166	Remission Status and Cortical Thickness in Childhood-Onset Schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 1133-1140.	0.5	21
167	Clozapine Versus High-Dose Olanzapine in Refractory Early-Onset Schizophrenia: An Open-Label Extension Study. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 307-316.	1.3	48
168	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 9-20.	0.5	274
169	Use of the Brief Psychiatric Rating Scale-Children (BPRS-C) as an Outcomes Measure in the Residential and Foster Care Setting. Residential Treatment for Children and Youth, 2008, 24, 243-259.	0.9	2

#	ARTICLE	IF	CITATIONS
170	Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. <i>American Journal of Psychiatry</i> , 2008, 165, 1420-1431.	7.2	414
171	Glycopyrrolate for Treatment of Clozapine-Induced Sialorrhea in Three Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 99-107.	1.3	22
173	Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 368-378.	0.8	6
174	New Findings on Antipsychotic Use in Children and Adolescents With Schizophrenia Spectrum Disorders. <i>American Journal of Psychiatry</i> , 2008, 165, 1369-1372.	7.2	4
175	Antipsychotic Treatment in Child and Adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 327-336.	1.3	58
176	GAD1 Single Nucleotide Polymorphism Is in Linkage Disequilibrium with a Child Bipolar I Disorder Phenotype. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 25-29.	1.3	20
177	A Comparative Pilot Study of Second-Generation Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 317-326.	1.3	41
178	Treatment of psychoses in children and adolescents. , 0, , 819-829.		0
179	Ethical issues in psychopharmacology of children and adolescents. <i>Current Opinion in Psychiatry</i> , 2008, 21, 598-605.	6.3	36
180	Drugs and other physical treatments. , 0, , 733-740.		0
181	SCHIZOPHRENIA, PHOBIAS, AND OBSESSIVE-COMPULSIVE DISORDER. , 2009, , 474-482.		0
182	CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY. , 2009, , 885-910.		1
183	Olanzapine compared to quetiapine in adolescents with a first psychotic episode. <i>European Child and Adolescent Psychiatry</i> , 2009, 18, 418-428.	4.7	66
184	Atypical and typical antipsychotics in the schools. <i>Psychology in the Schools</i> , 2009, 46, 869-884.	1.8	2
185	From bench to bedside: translating new research from genetics and neuroimaging into treatment development for early-onset schizophrenia. <i>Microbial Biotechnology</i> , 2009, 3, 243-258.	1.7	6
186	Child and Adolescent Psychopharmacology Update. <i>Psychiatric Clinics of North America</i> , 2009, 32, 111-133.	1.3	19
188	A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 611-621.	1.3	109
190	Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 60-70.	0.5	142

#	ARTICLE	IF	CITATIONS
191	Clozapine versus typical neuroleptic medication for schizophrenia. The Cochrane Library, 2009, , CD000059.	2.8	155
192	Use of Clozapine in an Adolescent With Refractory First-Episode Psychosis and Neutropenia. Journal of Clinical Psychopharmacology, 2010, 30, 336-338.	1.4	4
193	A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. International Clinical Psychopharmacology, 2010, 25, 1-6.	1.7	46
194	Prescribing antipsychotics for children and adolescents. Advances in Psychiatric Treatment, 2010, 16, 63-75.	0.5	12
195	Measuring outcomes of multiple diagnosis groups in residential treatment using the brief psychiatric rating scale for children (BPRS-C). Children and Youth Services Review, 2010, 32, 98-102.	1.9	3
196	Psychopharmacological Management of Children and Adolescents. , 2010, , 467-498.		0
197	Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatric Disease and Treatment, 2010, 6, 749.	2.2	14
198	Use of Metformin to Control Clozapine-Associated Weight Gain in an Adolescent with Schizoaffective Disorder. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 153-157.	1.3	6
199	Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia. Expert Opinion on Pharmacotherapy, 2010, 11, 195-205.	1.8	3
202	Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents. Revista De Psiquiatr�a Y Salud Mental (English Edition), 2010, 3, 152-167.	0.3	1
203	Semantic processing and thought disorder in childhood-onset schizophrenia: Insights from fMRI. Journal of Neurolinguistics, 2010, 23, 204-222.	1.1	23
205	Clinical Usefulness of Second-Generation Antipsychotics in Treating Children and Adolescents Diagnosed with Bipolar or Schizophrenic Disorders. Paediatric Drugs, 2011, 13, 291-302.	3.1	16
206	Treatment-refractory schizophrenia: what is it and what has been done about it?. Neuropsychiatry, 2011, 1, 325-347.	0.4	10
207	Antipsychotic drug toxicology in children. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 591-608.	3.3	28
208	Normalization of Cortical Gray Matter Deficits in Nonpsychotic Siblings of Patients With Childhood-Onset Schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 697-704.	0.5	57
209	Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 517-535.	1.3	221
210	Psychopharmacology of Schizophrenia in Children and Adolescents. Pediatric Clinics of North America, 2011, 58, 205-218.	1.8	11
211	Management of Schizophrenia in Children and Adolescents. Drugs, 2011, 71, 179-208.	10.9	78

#	ARTICLE	IF	CITATIONS
212	Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children. <i>Drug Safety</i> , 2011, 34, 651-668.	3.2	117
213	Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. <i>Psychiatry Research</i> , 2011, 189, 349-356.	3.3	18
214	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , 2011, 21, 621-645.	0.7	168
215	The use of Clozapine in Adolescents: A Case Report. <i>South African Journal of Psychiatry</i> , 2011, 17, 29.	0.4	0
217	Clinical relevance of findings in trials of antipsychotics: systematic review. <i>British Journal of Psychiatry</i> , 2011, 198, 341-345.	2.8	74
218	Cerebellar development in childhood onset schizophrenia and non-psychotic siblings. <i>Psychiatry Research - Neuroimaging</i> , 2011, 193, 131-137.	1.8	37
219	Age-Grouped Differences in Adverse Drug Events from Psychotropic Medication. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 299-309.	1.3	33
220	Missed Diagnosis of Tardive Dystonia in an Adolescent Girl Treated with Risperidone. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 191-194.	1.3	7
221	The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children and Adolescents: 2005-2009. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 537-543.	1.3	79
222	Symptom-Specific Rating Scales in Child and Adolescent Psychiatry Clinical Practice. <i>Child and Adolescent Psychopharmacology News</i> , 2011, 16, 6-8,10.	0.1	0
223	Psychiatric rating scales. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 227-237.	1.8	75
224	Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 309-316.	1.4	167
225	Comparative Effectiveness of Second-Generation Antipsychotic Medications in Early-Onset Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 845-853.	4.3	20
226	Antipsychotics for Children and Young Adults: A Comparative Effectiveness Review. <i>Pediatrics</i> , 2012, 129, e771-e784.	2.1	97
227	Adverse Effects and Toxicity of the Atypical Antipsychotics: What Is Important for the Pediatric Emergency Medicine Practitioner?. <i>Clinical Pediatric Emergency Medicine</i> , 2012, 13, 300-310.	0.4	28
228	Empirical Evidence for Psychopharmacologic Treatment in Early-Onset Psychosis and Schizophrenia. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2012, 21, 885-909.	1.9	8
229	Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 496-505.	0.5	37
230	Clozapine for the treatment of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1923-1935.	1.8	65

#	ARTICLE	IF	CITATIONS
231	Treatment of Early Onset Schizophrenia: Recent Trends, Challenges and Future Considerations. <i>Frontiers in Psychiatry</i> , 2012, 3, 29.	2.6	23
232	Using Multivariate Machine Learning Methods and Structural MRI to Classify Childhood Onset Schizophrenia and Healthy Controls. <i>Frontiers in Psychiatry</i> , 2012, 3, 53.	2.6	59
233	Antipsychotics in pediatric and adolescent patients: A review of comparative safety data. <i>Journal of Affective Disorders</i> , 2012, 138, S22-S30.	4.1	73
234	Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994–2010. <i>Microbial Biotechnology</i> , 2013, 7, 122-130.	1.7	39
235	Use of Clozapine in a State Child and Adolescent Psychiatric Hospital. <i>Psychiatric Quarterly</i> , 2013, 84, 343-349.	2.1	1
236	Risk Factors for Neutropenia in Clozapine-Treated Children and Adolescents with Childhood-Onset Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 110-116.	1.3	25
237	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 976-990.	0.5	213
238	Practitioner Review: Schizophrenia spectrum disorders and the at-risk mental state for psychosis in children and adolescents – evidence-based management approaches. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2013, 54, 1155-1175.	5.2	22
239	Psychopharmacologic Treatment of Psychosis in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2013, 22, 727-744.	1.9	21
241	“Clinical judgment” and the DSM-5 diagnosis of major depression. <i>World Psychiatry</i> , 2013, 12, 89-91.	10.4	44
242	Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents. <i>Paediatric Drugs</i> , 2013, 15, 217-233.	3.1	76
243	Antipsychotics in children and adolescents with schizophrenia: A systematic review and meta-analysis. <i>Indian Journal of Pharmacology</i> , 2013, 45, 439.	0.7	24
244	Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 278-293.	2.7	33
245	Lack of Gender Influence on Cortical and Subcortical Gray Matter Development in Childhood-Onset Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 52-58.	4.3	16
246	Treatment of adolescents with early-onset schizophrenia spectrum disorders. <i>Current Opinion in Psychiatry</i> , 2013, 26, 219-230.	6.3	82
247	Pediatric psychopharmacology: too much or too little?. <i>World Psychiatry</i> , 2013, 12, 118-123.	10.4	33
248	Treatments in context: transcranial direct current brain stimulation as a potential treatment in pediatric psychosis. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 447-458.	2.8	9
249	Atypical antipsychotics for psychosis in adolescents. <i>The Cochrane Library</i> , 2013, , CD009582.	2.8	37

#	ARTICLE	IF	CITATIONS
250	Hematological and Cardiometabolic Safety of Clozapine in the Treatment of Very Early Onset Schizophrenia: A Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 516-521.	1.3	11
252	Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations. <i>Trends in Psychiatry and Psychotherapy</i> , 2013, 35, 151-159.	0.8	9
253	Management of Clozapine-Induced Fever in a Child. <i>American Journal of Psychiatry</i> , 2014, 171, 398-402.	7.2	6
254	The use of antipsychotics in preschoolers: A veto or a sensible last option?. <i>Journal of Psychopharmacology</i> , 2014, 28, 303-319.	4.0	14
255	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , 2014, 14, 199.	2.6	10
256	Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. <i>European Psychiatry</i> , 2014, 29, 1-10.	0.2	74
257	Management of Adverse Effects of Second-generation Antipsychotics in Youth. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 84-105.	1.9	12
258	Antipsychotics use in children and adolescents: An on-going challenge in clinical practice. <i>Journal of Psychopharmacology</i> , 2014, 28, 615-623.	4.0	32
259	High rate of disease-related copy number variations in childhood onset schizophrenia. <i>Molecular Psychiatry</i> , 2014, 19, 568-572.	7.9	116
261	The Role and Efficacy of Clozapine Treatment in Early-Onset and Very Early-Onset Schizophrenia Cases: Discussion of Five Cases. <i>Journal of Microbiology and Biotechnology</i> , 2015, 25, 65-73.	2.1	1
262	Atypical antipsychotics in the treatment of early-onset schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 907.	2.2	12
263	15q13.3 duplication in two patients with childhood-onset schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 777-783.	1.7	27
264	A novel de novo mutation in <i>ATP1A3</i> and childhood-onset schizophrenia. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001008.	1.2	46
265	Melatonin and Other Neuroprotective Agents Target Molecular Mechanisms of Disease in Amyotrophic Lateral Sclerosis. , 2016, , 869-903.		1
266	Clozapine <i>v</i> . first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2016, 209, 385-392.	2.8	431
268	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine. <i>Human Psychopharmacology</i> , 2016, 31, 121-134.	1.5	19
269	Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice. <i>Journal of Neural Transmission</i> , 2016, 123, 1021-1031.	2.8	25
270	Current Treatment Trends of Psychosis in Youth with Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2016, 3, 1-14.	1.9	6

#	ARTICLE	IF	CITATIONS
271	Common polygenic variation and risk for childhood-onset schizophrenia. <i>Molecular Psychiatry</i> , 2016, 21, 94-96.	7.9	58
272	A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 815-821.	1.3	15
273	Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood-Onset Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 428-435.	1.3	22
274	Childhood-Onset Schizophrenia Spectrum Disorders. , 2017, , 107-122.		1
275	Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 772-777.	1.9	239
276	Use of Antipsychotic Drugs for Psychotic Disorders in Children. <i>Current Treatment Options in Psychiatry</i> , 2018, 5, 30-55.	1.9	3
277	Psychosis in Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 308-312.	0.5	28
278	A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 615-619.	1.3	13
279	A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 582-605.	1.3	46
280	Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. <i>European Neuropsychopharmacology</i> , 2018, 28, 659-674.	0.7	93
281	Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 661-678.	1.9	27
282	Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. <i>Journal of Psychopharmacology</i> , 2019, 33, 1187-1198.	4.0	28
283	S3-Leitlinie Schizophrenie. , 2019, , .		29
284	Optimizing Clozapine Benefit While Minimizing Adverse Effects with Concomitant Fluvoxamine Treatment in an Adolescent with Schizoaffective Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 66-71.	1.3	1
285	A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 403-412.	2.3	49
286	Off-Label Use of Clozapine in Children and Adolescentsâ€™A Literature Review. <i>American Journal of Therapeutics</i> , 2019, 26, e406-e416.	0.9	24
287	Treatment-Resistant Schizophrenia: Assessment and Management. , 2019, , 109-137.		0
288	Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 183-210.	1.9	16

#	ARTICLE	IF	CITATIONS
289	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. <i>Neuropsychopharmacology</i> , 2020, 45, 622-631.	5.4	63
290	État des lieux des modalités de prescription de la clozapine dans la schizophrénie à début précoce. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2020, 68, 431-439.	0.2	0
291	Sleep spindle activity in childhood onset schizophrenia: Diminished and associated with clinical symptoms. <i>Schizophrenia Research</i> , 2020, 223, 327-336.	2.0	15
292	Antipsychotics for Treatment of Adolescent Onset Schizophrenia: a Review. <i>Current Treatment Options in Psychiatry</i> , 2020, 7, 23-38.	1.9	2
293	Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 152.	2.6	13
294	Childhood Schizophrenia. , 2021, , 899-910.		0
295	Interest of Fluvoxamine as an Add-On to Clozapine in Children With Severe Psychiatric Disorder According to CYP Polymorphisms: Experience From a Case Series. <i>Frontiers in Psychiatry</i> , 2021, 12, 669446.	2.6	6
296	Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia". <i>Neuropsychopharmacology Reports</i> , 2021, 41, 266-324.	2.3	48
297	Investigating Predictors of Clozapine Response in Adolescents with Schizophrenia and Schizoaffective Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 504-510.	1.3	2
298	Child and Adolescent Onset Schizophrenia. , 0, , 34-53.		3
301	Child and Adolescent Psychiatric Disorders. , 2008, , 937-959.		5
305	Reasons for Hope for Children and Families: A Perspective and Overview. , 2002, , 3-15.		8
306	Community-Based Interventions in a System of Care and Outcomes Framework. , 2002, , 16-39.		32
307	What Is Case Management?. , 2002, , 41-68.		7
308	The Wraparound Approach. , 2002, , 69-90.		69
309	Multisystemic Therapy. , 2002, , 91-116.		11
310	Treatment Foster Care. , 2002, , 117-138.		41
311	Mentoring to Facilitate Resiliency in High-Risk Youth. , 2002, , 139-153.		5

#	ARTICLE	IF	CITATIONS
312	Family Support and Education. , 2002, , 154-177.		14
313	Special Education: Best Practices and First Step to Success. , 2002, , 179-197.		8
314	An Annotated Bibliography of Evidence for Diagnostic-Specific Psychosocial and Psychopharmacological Interventions. , 2002, , 212-276.		5
315	Psychopharmacology in the Context of Systems of Care. , 2002, , 277-301.		2
316	A Profitable Conjunction: From Science to Service in Children's Mental Health. , 2002, , 327-338.		73
317	Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive-compulsive disorders, autism, Tourette's and schizophrenia. Advances in Psychiatric Treatment, 2003, 9, 289-299.	0.5	9
318	The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS ONE, 2020, 15, e0243437.	2.5	28
319	Psicofarmacoterapia. Revista Brasileira De Psiquiatria, 2000, 22, 42-47.	1.7	7
320	Insomnia in Children. Paediatric Drugs, 2002, 4, 391-403.	3.1	1
321	Psychosis in children: diagnosis and treatment. Dialogues in Clinical Neuroscience, 2001, 3, 79-92.	3.7	30
322	Atypical Antipsychotic Drugs in Treatment-Refractory Schizophrenia. Psychiatric Annals, 1998, 28, 618-626.	0.1	10
323	Clozapine: Treatment of Mood Symptoms. Psychiatric Annals, 2002, 32, 722-729.	0.1	2
324	Treatment of Psychosis in Children and Adolescents. Psychiatric Annals, 2003, 33, 257-264.	0.1	3
325	Antipsychotic Medications for Children and Adolescents. Pediatric Annals, 2001, 30, 138-145.	0.8	24
326	Psychotic Disorders in Children and Adolescents: A Primer on Contemporary Evaluation and Management. primary care companion for CNS disorders, The, 2014, 16, .	0.6	22
327	Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care. Primary Care Companion To the Journal of Clinical Psychiatry, 2000, 2, 194-204.	0.6	30
328	Comparison of Aripiprazole Versus Haloperidol for the Treatment of Childhood and Adolescent Non-Affective Psychotic Disorders. Eastern Journal of Psychiatry, 2021, 16, 77-82.	0.0	0
329	Clozapin in der Kinder- und Jugendpsychiatrie Klinische Erfahrung und neue Befunde. , 2001, , 1-12.		0

#	ARTICLE	IF	CITATIONS
330	Treatment of the special patient with schizophrenia. Dialogues in Clinical Neuroscience, 2001, 3, 123-135.	3.7	1
331	Policy Implications Relevant to Implementing Evidence-Based Treatment. , 2002, , 303-326.		2
332	Integrated Cognitive-Behavior Therapy for Traumatic Stress Symptoms and Substance Abuse. , 2002, , 198-211.		0
333	Antipsychotic Agents. , 2002, , .		0
335	Children and adolescents. , 2005, , 205-227.		0
336	Use of Atypical Antipsychotics in Children & Adolescents. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 15-18.	0.6	0
338	La schizophrÃ©nie. , 2007, , 250-262.		0
339	Les neuroleptiques. , 2007, , 74-96.		0
340	Psychopharmakotherapie bei Kindern und Jugendlichen. , 2010, , 483-506.		1
343	Quel traitement pour l'enfant et l'adolescent schizophrÃ©nes?. , 2012, , 121-135.		0
346	Psychopharmacological Approaches. , 2013, , 37-56.		0
347	Disorders, Symptoms, and Their Pharmacotherapy. , 1999, , 183-209.		0
348	Neuroleptika in der Behandlung psychischer StÃ¶rungen im Kindes- und Jugendalter auÃerhalb schizophrener Krankheitsbilder. , 1999, , 63-79.		1
351	Schizophrenie bei Kindern, Jugendlichen und alten Menschen. , 2016, , 61-74.		0
352	Antipsychotic treatment and adherence in schizophrenia. , 2016, , 1-30.		0
354	Behandlung unter besonderen Bedingungen (Modul 4c). , 2019, , 181-254.		0
355	Pharmacotherapy in Special Situations. , 2019, , .		0
356	Pharmacotherapy in Special Situations. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
357	Evidence-Based Outcome for the Interventions in Childhood-Onset Schizophrenia. , 2020, , 319-337.		0
358	Schizophrenia in Children and Adolescents. , 2008, , 391-399.		0
359	Early onset schizophrenia: diagnostic dilemmas and treatment challenges. Therapy: Open Access in Clinical Medicine, 2004, 1, 131-147.	0.2	0
360	Current status of clozapine in the United States. Shanghai Archives of Psychiatry, 2012, 24, 110-3.	0.7	7
361	Conventional versus novel antipsychotics: changing concepts and clinical implications. Journal of Psychiatry and Neuroscience, 1999, 24, 431-41.	2.4	26
362	Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2011, 20, 218-33.	0.6	65
363	Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2012, 21, 302-9.	0.6	3
364	Clozapine Treatment and Cannabis Use in Adolescents with Psychotic Disorders - A Retrospective Cohort Chart Review. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2017, 26, 51-58.	0.6	5
365	Retrospective Review of Clozapine Use in Children and Adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 36-48.	0.6	2
366	Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders. Journal of Clinical Psychopharmacology, 2022, 42, 198-208.	1.4	8
367	Clozapine for Management of Childhood and Adolescent-Onset Schizophrenia: A Systematic Review and Meta-Analysis. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 2-11.	1.3	11
370	Clozapine and Risperidone in Chronic Schizophrenia: Effects on Symptoms, Parkinsonian Side Effects, and Neuroendocrine Response. American Journal of Psychiatry, 1999, 156, 294-298.	7.2	161
371	Including Children and Adolescents With Schizophrenia in Medication-Free Research. American Journal of Psychiatry, 1999, 156, 1065-1068.	7.2	21
372	Evidence of Clozapine's Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials. American Journal of Psychiatry, 1999, 156, 990-999.	7.2	275
373	Neurobiology of Childhood-Onset Schizophrenia. , 2008, 4, 55-61.		0
378	Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution. , 2019, , 276-306.		0
379	Enhanced recognition of adolescents with schizophrenia and a computational contrast of their neuroanatomy with healthy patients using brainwave signals. Applied AI Letters, 2023, 4, .	2.2	2
380	Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis. British Journal of Psychiatry, 2023, 223, 282-294.	2.8	4

#	ARTICLE	IF	CITATIONS
381	Lost in Translation: Challenges in the Diagnosis and Treatment of Early-Onset Schizophrenia. Cureus, 2023, , .	0.5	1
382	A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 0, , .	3.2	5
383	A Systematic Review of Clozapine Concentrationâ€Dose Ratio from Therapeutic Drug Monitoring Studies in Children and Adolescents Treated with Clozapine for Mental Disorders. Therapeutic Drug Monitoring, 0, , .	2.0	0